Literature DB >> 30994339

Arsenic in Rice Bran Products: In Vitro Oral Bioaccessibility, Arsenic Transformation by Human Gut Microbiota, and Human Health Risk Assessment.

Naiyi Yin1,2, Pengfei Wang1,2, Yan Li1,2, Huili Du1,2, Xiaochen Chen3, Guoxin Sun2, Yanshan Cui1,2.   

Abstract

Despite rice consumption, rice bran as a byproduct of rice milling contains higher arsenic (As). The present study evaluated the metabolic potency of in vitro cultured human colon microbiota toward As from five rice bran products with 0.471-1.491 mg of As/kg. Arsenic bioaccessibility ranged from 52.8 to 78.8% in the gastric phase, and a 1.2-fold increase (66.0-95.8%) was observed upon the small intestinal phase. Subsequently, a significant decline of As bioaccessibility (11.3-63.6%) and a high methylation percentage of 18.5-79.8% were found in the colon phase. The predominant As species in the solid phase was always As(V) (49.6-63.4%), and As-thiolate complexes increased by 10% at the end of colon incubation. Human gut microbiota could induce As bioaccessibility lowering and As transformation in rice bran, which illustrated the importance of food-bound As metabolism in the human body. This will result in a better understanding of health implications associated with As exposures.

Entities:  

Keywords:  Simulator of the Human Intestinal Microbial Ecosystem; arsenic; bioaccessibility; colon; health risk; rice bran; speciation

Mesh:

Substances:

Year:  2019        PMID: 30994339     DOI: 10.1021/acs.jafc.9b02008

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  2 in total

Review 1.  Rice Intake and Emerging Concerns on Arsenic in Rice: a Review of the Human Evidence and Methodologic Challenges.

Authors:  Margaret R Karagas; Tracy Punshon; Matt Davis; Catherine M Bulka; Francis Slaughter; Despina Karalis; Maria Argos; Habibul Ahsan
Journal:  Curr Environ Health Rep       Date:  2019-12

2.  Arsenic Accumulation of Realgar Altered by Disruption of Gut Microbiota in Mice.

Authors:  Wenfeng Xu; Shanshan Zhang; Wenqing Jiang; Shuo Xu; Pengfei Jin
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-18       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.